<p>蒙特利尔，魁北克 --（Newsfile Corp. -2026 年 2 月 10 日）- Defence Therapeutics Inc.（CSE: DTC）（FSE: DTC）（OTCQB: DTCFF）（&#34;Defence&#34;或&#34;公司&#34;），一家公开交易的生物技术和精准细胞内药物递送公司，报告了其于 2026 年 1 月 30 日举行的科学顾问委员会（&#34;SAB&#34;）会议，会议重点讨论了 Accum®在抗体药物偶联物（&#34;ADC&#34;）应用中的战略定位。</p>
<p>此次讨论汇聚了在 ADC 化学与开发、实验设计与转化科学、价值创造与合作战略等领域的互补专业知识，使得对 Accum®在改善 ADC 药物载荷细胞内递送中的作用进行了深入且富有建设性的交流。讨论集中在识别最关键的科学问题、细化开发优先事项以及将数据生成与未来临床和制药合作伙伴的期望对齐。</p>
<p>&#34;这次讨论极具价值，帮助我们明确了科学重点和战略方向，&#34; Defence Therapeutics 的首席科学官 Maxime Parisotto 博士表示。&#34;我们的顾问分享的见解直接影响了我们设计下一步研究的方式，确保我们生成对推进 Accum®进入临床和为平台建立有意义的合作关系最重要的数据。&#34;</p>
<p>此次讨论受益于 Rob Leanna 博士的互补专业知识，他在 AbbVie 的长期任职期间积累了 ADC 开发、药物连接化学和临床推进方面的经验；Danny Chui 博士则带来了在 Zymeworks、Abdera Therapeutics 和 Kairos Therapeutics 的重大工作所提供的对 ADC 设计和转化科学的深刻见解；Brendan Hussey 博士则从临床开发、战略和资本形成的角度贡献了价值创造与合作的视角。他们的意见共同指导了 Accum®开发的下一个阶段，推动平台向临床转化和战略合作伙伴关系发展。</p>
<p>通过这次多学科的对话，Defence Therapeutics 正在细化其 Accum® ADC 开发路线图，以更好地将平台能力与临床开发要求和合作考虑对齐，目标是实现更有效且耐受性更好的 ADC 疗法。这一方法强化了 Accum®作为复杂生物制剂下一代细胞内递送解决方案的潜力。如需探索合作机会或安排会议，请联系 info@defencetherapeutics.com。</p>
<p><strong>关于 Defence Therapeutics：</strong></p>
<p>Defence Therapeutics 是一家公开交易的生物技术公司，致力于使癌症治疗更加有效和安全。通过其 Accum®精准药物递送平台，Defence 正在努力提高 ADC 和其他复杂生物制剂在较低剂量下的效力，旨在减少副作用并改善对先进疗法的获取。通过追求前沿科学，并与制药和生物技术合作伙伴合作，Defence 力求为最需要的患者带来变革性疗法。欲了解更多关于 Defence Therapeutics 的信息并探索合作机会，请访问 www.defencetherapeutics.com 或联系 info@defencetherapeutics.com。</p>
<p><strong>关于 “前瞻性” 信息的警示声明</strong></p>
<p>本发布包含某些可能被视为 “前瞻性声明” 的内容。除历史事实外，本发布中的所有声明，涉及公司预期发生的事件或发展，均为前瞻性声明。前瞻性声明是指非历史事实的声明，通常但不总是通过 “预期”、“计划”、“预计”、“相信”、“打算”、“估计”、“项目”、“潜在” 等词语或 “将”、“会”、“可能”、“可以” 或 “应该” 发生的事件或条件来识别。尽管公司相信这些前瞻性声明中表达的期望基于合理假设，但这些声明并不保证未来的表现，实际结果可能与前瞻性声明中的结果有实质性差异。可能导致实际结果与前瞻性声明中的结果有实质性差异的因素包括监管行动、市场价格、资本和融资的持续可用性，以及一般经济、市场或商业条件。投资者被警告，任何此类声明都不保证未来的表现，实际结果或发展可能与前瞻性声明中预测的结果有实质性差异。前瞻性声明基于公司管理层在声明发布时的信念、估计和意见。除适用证券法要求外，公司没有义务在管理层的信念、估计或意见或其他因素发生变化时更新这些前瞻性声明。</p>
<p>CSE 及其市场监管机构（根据 CSE 政策的定义）对本发布的充分性或准确性不承担责任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/282529_ea22eb4d94dabb52_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/282529_ea22eb4d94dabb52_logo.jpg"/></p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/282529</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/282529/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/282529/375"/></p>

动态生物技术与基因组 ETF - Invesco

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Defence Therapeutics Inc. 于 2026 年 1 月 30 日召开了科学顾问委员会会议，以推进其 Accum® ADC 战略。专家们讨论了 ADC 化学、开发和临床合作伙伴关系，完善了 Accum® 的开发路线图，以增强 ADC 荷载的细胞内递送。获得的见解将为未来的研究提供信息，并与临床和制药合作伙伴的期望保持一致。Defence 旨在提高 ADC 疗法的有效性和耐受性，将 Accum® 定位为癌症治疗的下一代解决方案。如需合作咨询，请联系 info@defencetherapeutics.com</p>

<p>Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (&#34;Defence&#34; or the &#34;Company&#34;), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board (&#34;SAB&#34;) meeting held on January 30, 2026, focused on advancing the strategic positioning of Accum® for antibody-drug conjugate (&#34;ADC&#34;) applications.</p>
<div class="lb-trans"><p>蒙特利尔，魁北克 --（Newsfile Corp. -2026 年 2 月 10 日）- Defence Therapeutics Inc.（CSE: DTC）（FSE: DTC）（OTCQB: DTCFF）（&#34;Defence&#34;或&#34;公司&#34;），一家公开交易的生物技术和精准细胞内药物递送公司，报告了其于 2026 年 1 月 30 日举行的科学顾问委员会（&#34;SAB&#34;）会议，会议重点讨论了 Accum®在抗体药物偶联物（&#34;ADC&#34;）应用中的战略定位。</p>
</div><p>The discussion brought together complementary expertise spanning ADC chemistry and development, experimental design and translational science, and value creation and partnering strategy, enabling an in-depth and highly constructive exchange on Accum®'s role in improving intracellular delivery of ADC payloads. The conversation focused on identifying the most critical scientific questions to address, refining development priorities, and aligning data generation with the expectations of future clinical and pharmaceutical partners.</p>
<div class="lb-trans"><p>此次讨论汇聚了在 ADC 化学与开发、实验设计与转化科学、价值创造与合作战略等领域的互补专业知识，使得对 Accum®在改善 ADC 药物载荷细胞内递送中的作用进行了深入且富有建设性的交流。讨论集中在识别最关键的科学问题、细化开发优先事项以及将数据生成与未来临床和制药合作伙伴的期望对齐。</p>
</div><p>&#34;This was an exceptionally valuable discussion that helped us sharpen both our scientific focus and our strategic direction,&#34; said Maxime Parisotto, PhD, Chief Scientific Officer of Defence Therapeutics. &#34;The insights shared by our advisors are directly informing how we design our next studies, ensuring that we generate the data that matter most to advance Accum® toward the clinic and position the platform for meaningful partnerships.&#34;</p>
<div class="lb-trans"><p>&#34;这次讨论极具价值，帮助我们明确了科学重点和战略方向，&#34; Defence Therapeutics 的首席科学官 Maxime Parisotto 博士表示。&#34;我们的顾问分享的见解直接影响了我们设计下一步研究的方式，确保我们生成对推进 Accum®进入临床和为平台建立有意义的合作关系最重要的数据。&#34;</p>
</div><p>The discussion benefited from the complementary expertise of Rob Leanna, PhD, whose experience in ADC development, drug-linker chemistry, and clinical advancement was shaped through his long tenure at AbbVie; Danny Chui, PhD, who brought deep insight into ADC design and translational science informed by his significant work at Zymeworks, Abdera Therapeutics, and Kairos Therapeutics; and Brendan Hussey, PhD, who contributed a value-creation and partnering perspective grounded in clinical development, strategy, and capital formation. Together, their input is guiding the next phase of Accum® development as the platform advances toward clinical translation and strategic partnerships.</p>
<div class="lb-trans"><p>此次讨论受益于 Rob Leanna 博士的互补专业知识，他在 AbbVie 的长期任职期间积累了 ADC 开发、药物连接化学和临床推进方面的经验；Danny Chui 博士则带来了在 Zymeworks、Abdera Therapeutics 和 Kairos Therapeutics 的重大工作所提供的对 ADC 设计和转化科学的深刻见解；Brendan Hussey 博士则从临床开发、战略和资本形成的角度贡献了价值创造与合作的视角。他们的意见共同指导了 Accum®开发的下一个阶段，推动平台向临床转化和战略合作伙伴关系发展。</p>
</div><p>As a result of this multidisciplinary dialogue, Defence Therapeutics is refining its Accum® ADC development roadmap to better align platform capabilities with clinical development requirements and partnering considerations, with the goal of enabling more effective and better-tolerated ADC therapies. This approach reinforces Accum®'s potential as a next-generation intracellular delivery solution for complex biologics. To explore partnering opportunities or schedule a meeting, please contact info@defencetherapeutics.com.</p>
<div class="lb-trans"><p>通过这次多学科的对话，Defence Therapeutics 正在细化其 Accum® ADC 开发路线图，以更好地将平台能力与临床开发要求和合作考虑对齐，目标是实现更有效且耐受性更好的 ADC 疗法。这一方法强化了 Accum®作为复杂生物制剂下一代细胞内递送解决方案的潜力。如需探索合作机会或安排会议，请联系 info@defencetherapeutics.com。</p>
</div><p><strong>About Defence Therapeutics:</strong></p>
<div class="lb-trans"><p><strong>关于 Defence Therapeutics：</strong></p>
</div><p>Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.</p>
<div class="lb-trans"><p>Defence Therapeutics 是一家公开交易的生物技术公司，致力于使癌症治疗更加有效和安全。通过其 Accum®精准药物递送平台，Defence 正在努力提高 ADC 和其他复杂生物制剂在较低剂量下的效力，旨在减少副作用并改善对先进疗法的获取。通过追求前沿科学，并与制药和生物技术合作伙伴合作，Defence 力求为最需要的患者带来变革性疗法。欲了解更多关于 Defence Therapeutics 的信息并探索合作机会，请访问 www.defencetherapeutics.com 或联系 info@defencetherapeutics.com。</p>
</div><p><strong>Cautionary Statement Regarding &#34;Forward-Looking&#34; Information</strong></p>
<div class="lb-trans"><p><strong>关于 “前瞻性” 信息的警示声明</strong></p>
</div><p>This release includes certain statements that may be deemed &#34;forward-looking statements&#34;. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words &#34;expects&#34;, &#34;plans&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;estimates&#34;, &#34;projects&#34;, &#34;potential&#34; and similar expressions, or that events or conditions &#34;will&#34;, &#34;would&#34;, &#34;may&#34;, &#34;could&#34; or &#34;should&#34; occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.</p>
<div class="lb-trans"><p>本发布包含某些可能被视为 “前瞻性声明” 的内容。除历史事实外，本发布中的所有声明，涉及公司预期发生的事件或发展，均为前瞻性声明。前瞻性声明是指非历史事实的声明，通常但不总是通过 “预期”、“计划”、“预计”、“相信”、“打算”、“估计”、“项目”、“潜在” 等词语或 “将”、“会”、“可能”、“可以” 或 “应该” 发生的事件或条件来识别。尽管公司相信这些前瞻性声明中表达的期望基于合理假设，但这些声明并不保证未来的表现，实际结果可能与前瞻性声明中的结果有实质性差异。可能导致实际结果与前瞻性声明中的结果有实质性差异的因素包括监管行动、市场价格、资本和融资的持续可用性，以及一般经济、市场或商业条件。投资者被警告，任何此类声明都不保证未来的表现，实际结果或发展可能与前瞻性声明中预测的结果有实质性差异。前瞻性声明基于公司管理层在声明发布时的信念、估计和意见。除适用证券法要求外，公司没有义务在管理层的信念、估计或意见或其他因素发生变化时更新这些前瞻性声明。</p>
</div><p>Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.</p>
<div class="lb-trans"><p>CSE 及其市场监管机构（根据 CSE 政策的定义）对本发布的充分性或准确性不承担责任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/282529_ea22eb4d94dabb52_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/8000/282529_ea22eb4d94dabb52_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282529</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/282529</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/282529/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/282529/375"/></p>

Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board | DTCFF Stock News

StockTitan

美国制药 ETF - iShares

医药突破 ETF - ALPS

Solo Brands

Therapeutics MD

Turn Therapeutics

医疗业 ETF - Vanguard

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

标普全球医疗股指数 ETF - iShares

医疗业 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

Defence Therapeutics 通过多学科科学顾问委员会调整其累积 ADC 策略 | DTCFF 股票新闻